BioMarin
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade BioMarin 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMRN
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.
CEOAlexander Hardy
CEOAlexander Hardy
Employees3,040
Employees3,040
HeadquartersSan Rafael, California
HeadquartersSan Rafael, California
Founded1997
Founded1997
Employees3,040
Employees3,040
BMRN Key Statistics
Market cap11.56B
Market cap11.56B
Price-Earnings ratio22.04
Price-Earnings ratio22.04
Dividend yield—
Dividend yield—
Average volume1.93M
Average volume1.93M
High today$60.48
High today$60.48
Low today$58.84
Low today$58.84
Open price$59.31
Open price$59.31
Volume1.32M
Volume1.32M
52 Week high$94.85
52 Week high$94.85
52 Week low$52.93
52 Week low$52.93
BMRN News
TipRanks 2d
BioMarin’s Strategic Acquisition of Inozyme Boosts Growth Prospects and Stock Price TargetAnalyst William Pickering of Bernstein maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), boosting the price target to $95.00. Confid...
TipRanks 4d
BioMarin Pharmaceutical: Balancing Opportunities and Risks Amid Inozyme Acquisition and Market ChallengesWilliam Blair analyst Sami Corwin has maintained their neutral stance on BMRN stock, giving a Hold rating on May 2. Confident Investing Starts Here: Quickly a...
TipRanks 4d
Inozyme downgraded to Hold from Buy at JefferiesJefferies downgraded Inozyme (INZY) to Hold from Buy with a price target of $4, down from $15, after BioMarin Pharmaceutical (BMRN) agreed to acquire the compan...
Analyst ratings
81%
of 31 ratingsBuy
80.6%
Hold
19.4%
Sell
0%
More BMRN News
TipRanks 4d
Leerink bullish on BioMarin following Inozyme deal, expects additional BDLeerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it a nice addition to the company’s ER...
People also own
Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.